[go: up one dir, main page]

MX2021005992A - Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. - Google Patents

Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.

Info

Publication number
MX2021005992A
MX2021005992A MX2021005992A MX2021005992A MX2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A
Authority
MX
Mexico
Prior art keywords
depression
gaboxadol
suicide
reducing risk
rapid relief
Prior art date
Application number
MX2021005992A
Other languages
English (en)
Inventor
Pavel Osten
Kristin Baldwin
Original Assignee
Certego Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Certego Therapeutics Inc filed Critical Certego Therapeutics Inc
Publication of MX2021005992A publication Critical patent/MX2021005992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos y composiciones para reducir rápidamente el riesgo de suicidio en pacientes que sufren de tendencias suicidas agudas, y para aliviar rápidamente los síntomas del estado de ánimo en la depresión mayor y la depresión resistente al tratamiento, utilizando un nuevo régimen terapéutico que comprende una administración única o intermitente de una dosis elevada de gaboxadol, o una sal farmacéuticamente aceptable del mismo, al sujeto que lo necesite.
MX2021005992A 2018-11-21 2019-11-21 Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. MX2021005992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770287P 2018-11-21 2018-11-21
PCT/US2019/062554 WO2020106927A1 (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Publications (1)

Publication Number Publication Date
MX2021005992A true MX2021005992A (es) 2021-09-14

Family

ID=70728606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005992A MX2021005992A (es) 2018-11-21 2019-11-21 Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.

Country Status (13)

Country Link
US (3) US11123332B2 (es)
EP (1) EP3883566A4 (es)
JP (1) JP2022514194A (es)
KR (1) KR20210110585A (es)
CN (1) CN113395962A (es)
AU (1) AU2019384157A1 (es)
BR (1) BR112021009944A2 (es)
CA (1) CA3120856A1 (es)
GB (1) GB2594616A (es)
IL (1) IL283311A (es)
MX (1) MX2021005992A (es)
SG (1) SG11202105358RA (es)
WO (1) WO2020106927A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
AU2017229656B2 (en) 2016-03-08 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MX2019001669A (es) * 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
CN113395962A (zh) * 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200501951A (en) 2003-06-25 2005-01-16 Lundbeck & Co As H Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
EP2145620A3 (en) 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
TW200509918A (en) 2003-06-25 2005-03-16 Lundbeck & Co As H Treatment of depression and other affective disorders
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06011325A (es) 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
ZA200607427B (en) 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20080159958A1 (en) * 2006-12-27 2008-07-03 Abbott Laboratories Determination of histamine-3 bioactivity
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
GB0810063D0 (en) 2008-06-03 2008-07-09 Renovo Ltd Medicaments and methods for inhibition of scarring
CA2732636A1 (en) 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
ES2836905T3 (es) * 2014-03-31 2021-06-28 Univ Maryland Uso de moduladores negativos de los receptores gaba que contienen subunidades alfa5 como antidepresivos de acción rápida
WO2015171547A1 (en) 2014-05-05 2015-11-12 Ovid Therapeutics Inc. Methods of treating cognitive impairment associated with neurodegenerative disorders
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
US20170304358A1 (en) 2014-10-06 2017-10-26 Seyyed Nassir GHAEMI Primary and secondary prevention of dementias and suicide with trace dose lithium
US10626123B2 (en) 2015-03-24 2020-04-21 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol
WO2016176609A1 (en) 2015-04-30 2016-11-03 Ovid Therapeutics Inc Methods of treating prader-willi syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
AR105378A1 (es) 2015-07-17 2017-09-27 Ovid Therapeutics Inc Métodos de tratamiento de trastornos del desarrollo con gaboxadol
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
AR105670A1 (es) 2015-08-11 2017-10-25 Ovid Therapeutics Inc Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
CN108135889A (zh) 2015-08-11 2018-06-08 奥维德医疗公司 用于在危重监护治疗期间使用的镇静方法和肠胃外制剂
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US20170119704A1 (en) 2015-10-13 2017-05-04 Ovid Therapeutics Inc. Treatment of cognitive impairment
JP2019517469A (ja) 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10737984B2 (en) 2016-11-30 2020-08-11 Hrl Laboratories, Llc Formulations and methods for 3D printing of ceramic matrix composites
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3595669A4 (en) 2017-03-15 2021-03-03 Ovid Therapeutics Inc. USE OF TAILOR-MADE RECEPTORS ACTIVATED EXCLUSIVELY BY CUSTOM-MADE MEDICINES IN THE TREATMENT OF EPILEPTIC DISORDERS
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
WO2018222957A1 (en) 2017-06-01 2018-12-06 Ovid Therapeutics Inc. Treatment of developmental disorders with imidazolone derivatives
US20190000993A1 (en) 2017-06-28 2019-01-03 Ovid Therapeutics Inc. Treatment of developmental syndromes
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
CN111163811A (zh) 2017-08-25 2020-05-15 奥维德医疗公司 重组腺相关载体
WO2019055369A1 (en) 2017-09-12 2019-03-21 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA
CN107595850A (zh) 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种有效提高睡眠质量的药物组合物及其用途
AU2019249277A1 (en) 2018-04-06 2020-10-22 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders
CN113395962A (zh) * 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症

Also Published As

Publication number Publication date
SG11202105358RA (en) 2021-06-29
BR112021009944A2 (pt) 2021-08-17
US11123332B2 (en) 2021-09-21
GB202108720D0 (en) 2021-08-04
KR20210110585A (ko) 2021-09-08
AU2019384157A1 (en) 2021-06-17
US20220008398A1 (en) 2022-01-13
US20220054461A1 (en) 2022-02-24
JP2022514194A (ja) 2022-02-10
WO2020106927A1 (en) 2020-05-28
CN113395962A (zh) 2021-09-14
US20200155522A1 (en) 2020-05-21
CA3120856A1 (en) 2020-05-28
EP3883566A1 (en) 2021-09-29
IL283311A (en) 2021-07-29
GB2594616A (en) 2021-11-03
EP3883566A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2021002321A (es) Nuevos metodos.
MX2020009773A (es) Terapia de combinacion.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2009008582A (es) Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
RU2017134443A (ru) Способ лечения с применением традипитанта
NZ750752A (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12020551726A1 (en) Treatment of atopic dermatitis
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
EP4316589A3 (en) Treatment of patients with classic fabry disease
ZA202209104B (en) Intradialytic use of sodium thiosulfate
TN2022000185A1 (en) Methods of treating splenomegaly
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.